Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: Are these conditions related to vascular dysfunction?

International Journal of Urology

Volumn 21, Issue 9, 2014, Pages 856-864

  Shimizu, Shogo ^a   Tsounapi, Panagiota ^b   Shimizu, Takahiro ^a   Honda, Masashi ^b   Inoue, Keiji ^a   Dimitriadis, Fotios ^c   Saito, Motoaki ^a  

^a KOCHI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Benign prostatic enlargement; Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; Pelvic blood flow; Urinary bladder

Indexed keywords

AGING; ATHEROSCLEROSIS; BLADDER DYSFUNCTION; BLADDER ISCHEMIA; BLOOD FLOW; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PELVIS; PENIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; COMPLICATION; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; URINARY BLADDER DISEASES; VASCULAR DISEASE;

ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; PROSTATIC HYPERPLASIA; URINARY BLADDER DISEASES; VASCULAR DISEASES;

EID: 84906937569     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12501     Document Type: Review

References (86)

1. Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int. 2005; 95 (Suppl 4): 12-18.
2. Ponholzer A, Temml C, Wehrberger C etal. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur. Urol. 2006; 50: 581-586.
3. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. Rev. Urol. 2010; 12: e157-180.
4. Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur. Urol. 2009; 55: 38-48.
5. Berger AP, Deibl M, Leonhartsberger N etal. Vascular damage as a risk factor for benign prostatic hyperplasia and erectile dysfunction. BJU Int. 2005; 96: 1073-1078.
6. Braun MH, Sommer F, Haupt G etal. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey". Eur. Urol. 2003; 44: 588-594.
7. Tarcan T, Azadzoi KM, Siroky MB etal. Age-related erectile and voiding dysfunction: the role of arterial insufficiency. Br. J. Urol. 1998; 82 (Suppl 1): 26-33.
8. Yono M, Tanaka T, Tsuji S etal. Effects of age and hypertension on alpha1-adrenoceptors in the major source arteries of the rat bladder and penis. Eur. J. Pharmacol. 2011; 670: 260-265.
9. Yono M, Yamamoto Y, Yoshida M etal. Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract. Life Sci. 2007; 81: 218-222.
10. Saito M, Tsounapi P, Oikawa R etal. Prostatic ischemia induces ventral prostatic hyperplasia in the SHR; possible mechanism of development of BPH. Sci. Rep. 2014; 4. doi: 10.1038/srep03822.
11. Siroky MB. The aging bladder. Rev. Urol. 2004; 6 (Suppl 1): S3-7.
12. De EJ, Hou P, Estrera AL etal. Pelvic ischemia is measurable and symptomatic in patients with coronary artery disease: a novel application of dynamic contrast-enhanced magnetic resonance imaging. J. Sex. Med. 2008; 5: 2635-2645.
13. Pinggera GM, Mitterberger M, Steiner E etal. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int. 2008; 102: 470-474.
14. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. 2003; 170: 530-547.
15. Abrams P, Cardozo L, Fall M etal. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 2002; 21: 167-178.
16. Casabe A, Roehrborn CG, Da Pozzo LF etal. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J. Urol. 2014; 191: 727-733.
17. Verhamme KM, Dieleman JP, Bleumink GS etal. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur. Urol. 2002; 42: 323-328.
18. Coyne KS, Sexton CC, Thompson CL etal. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009; 104: 352-360.
19. Irwin DE, Milsom I, Hunskaar S etal. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006; 50: 1306-1314; discussion 1314-15.
20. Fibbi B, Morelli A, Vignozzi L etal. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J. Sex. Med. 2010; 7: 59-69.
21. Filippi S, Morelli A, Sandner P etal. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-1029.
22. Kedia GT, Uckert S, Jonas U etal. The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J. Urol. 2008; 26: 603-609.
23. Saito M, Ohmasa F, Dimitriadis F etal. Hydroxyfasudil ameliorates penile dysfunction in the male spontaneously hypertensive rat. Pharmacol. Res. 2012; 66: 325-331.
24. Saito M, Ohmasa F, Tsounapi P etal. Nicorandil ameliorates hypertension-related bladder dysfunction in the rat. Neurourol. Urodyn. 2012; 31: 695-701.
25. Pinggera GM, Mitterberger M, Pallwein L etal. alpha-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int. 2008; 101: 319-324.
26. Wada N, Watanabe M, Kita M etal. Analysis of bladder vascular resistance before and after prostatic surgery in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Neurourol. Urodyn. 2012; 31: 659-663.
27. Azadzoi KM, Tarcan T, Kozlowski R etal. Overactivity and structural changes in the chronically ischemic bladder. J. Urol. 1999; 162: 1768-1778.
28. Nomiya M, Sagawa K, Yazaki J etal. Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol. Urodyn. 2012; 31: 185-189.
29. Lin AT, Chen MT, Yang CH etal. Blood flow of the urinary bladder: effects of outlet obstruction and correlation with bioenergetic metabolism. Neurourol. Urodyn. 1995; 14: 285-292.
30. Matsumoto S, Kakizaki H. Causative significance of bladder blood flow in lower urinary tract symptoms. Int. J. Urol. 2012; 19: 20-25.
31. Azadzoi KM, Shinde VM, Tarcan T etal. Increased leukotriene and prostaglandin release, and overactivity in the chronically ischemic bladder. J. Urol. 2003; 169: 1885-1891.
32. Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J. Urol. 2007; 178: 710-715.
33. Masuda H, Kihara K, Saito K etal. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008; 101: 775-780.
34. Andersson KE. Storage and voiding symptoms: pathophysiologic aspects. Urology 2003; 62: 3-10.
35. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J. Urol. 2001; 166: 550-552; discussion 553.
36. Chancellor MB, Rivas DA. American Urological Association symptom index for women with voiding symptoms: lack of index specificity for benign prostate hyperplasia. J. Urol. 1993; 150: 1706-1708; discussion 1708-9.
37. Chapple CR, Wein AJ, Abrams P etal. Lower urinary tract symptoms revisited: a broader clinical perspective. Eur. Urol. 2008; 54: 563-569.
38. Kaplan SA. Male pelvic health: a urological call to arms. J. Urol. 2006; 176: 2351-2352.
39. Mariappan P, Chong WL. Prevalence and correlations of lower urinary tract symptoms, erectile dysfunction and incontinence in men from a multiethnic Asian population: results of a regional population-based survey and comparison with industrialized nations. BJU Int. 2006; 98: 1264-1268.
40. Yamaguchi O, Nomiya M, Andersson KE. Functional consequences of chronic bladder ischemia. Neurourol. Urodyn. 2014; 33: 54-58.
41. Azadzoi KM, Chen BG, Radisavljevic ZM etal. Molecular reactions and ultrastructural damage in the chronically ischemic bladder. J. Urol. 2011; 186: 2115-2122.
42. Azadzoi KM, Tarcan T, Siroky MB etal. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and non-compliance in the rabbit. J. Urol. 1999; 161: 1626-1635.
43. Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br. J. Urol. 1994; 73: 3-8.
44. Yoshida M, Masunaga K, Nagata T etal. The effects of chronic hyperlipidemia on bladder function in myocardial infarction-prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits. Neurourol. Urodyn. 2010; 29: 1350-1354.
45. Das AK, Leggett RE, Whitbeck C etal. Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol. Urodyn. 2002; 21: 160-166.
46. Okutsu H, Matsumoto S, Ohtake A etal. Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity. J. Urol. 2011; 186: 2470-2477.
47. Inoue S, Saito M, Takenaka A. Hydroxyfasudil ameliorates bladder dysfunction in male spontaneously hypertensive rats. Urology 2012; 79: 1186 e9-14.
48. Inoue S, Saito M, Tsounapi P etal. Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. BJU Int. 2012; 110: E118-124.
49. Saito M, Shimizu S, Ohmasa F etal. Characterization of silodosin and naftopidil in the treatment of bladder dysfunction in the spontaneously hypertensive rat. Neurourol. Urodyn. 2013; 32: 393-398.
50. Nomiya M, Yamaguchi O, Akaihata H etal. Progressive vascular damage may lead to bladder underactivity in rats. J. Urol. 2014; 191: 1462-1469.
51. Sawada N, Nomiya M, Hood B etal. Protective effect of a beta3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur. Urol. 2013; 64: 664-671.
52. Goi Y, Tomiyama Y, Nomiya M etal. Effects of silodosin, a selective alpha1A-adrenoceptor antagonist, on bladder blood flow and bladder function in a rat model of atherosclerosis induced chronic bladder ischemia without bladder outlet obstruction. J. Urol. 2013; 190: 1116-1122.
53. Matsui T, Oka M, Fukui T etal. Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia. Int. J. Urol. 2012; 19: 669-675.
54. Abrams P. LUTS, BPH, BPE, BPO: a plea for the logical use of correct terms. Rev. Urol. 1999; 1: 65.
55. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev. Urol. 2005; 7 (Suppl 9): S3-S14.
56. Calais Da Silva F, Marquis P, Deschaseaux P etal. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur. Urol. 1997; 31: 272-280.
57. Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N. Engl. J. Med. 2012; 367: 248-257.
58. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp. Gerontol. 2005; 40: 121-128.
59. De Marzo AM, Coffey DS, Nelson WG. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 1999; 53: 29-39; discussion 39-42.
60. Steiner MS, Couch RC, Raghow S etal. The chimpanzee as a model of human benign prostatic hyperplasia. J. Urol. 1999; 162: 1454-1461.
61. Michel MC, Heemann U, Schumacher H etal. Association of hypertension with symptoms of benign prostatic hyperplasia. J. Urol. 2004; 172: 1390-1393.
62. Bourke JB, Griffin JP. Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy. Br. J. Urol. 1966; 38: 18-23.
63. Kwon H, Kang HC, Lee JH. Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 2013; 81: 1325-1329.
64. De Nunzio C, Aronson W, Freedland SJ etal. The correlation between metabolic syndrome and prostatic diseases. Eur. Urol. 2012; 61: 560-570.
65. Ghafar MA, Puchner PJ, Anastasiadis AG etal. Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr. Urol. Rep. 2002; 3: 292-296.
66. Berger AP, Bartsch G, Deibl M etal. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int. 2006; 98: 1038-1042.
67. Berger AP, Horninger W, Bektic J etal. Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease? BJU Int. 2006; 98: 587-590.
68. Lue TF, Giuliano F, Montorsi F etal. Summary of the recommendations on sexual dysfunctions in men. J. Sex. Med. 2004; 1: 6-23.
69. Feldman HA, Goldstein I, Hatzichristou DG etal. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. 1994; 151: 54-61.
70. Doumas M, Tsakiris A, Douma S etal. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J. Androl. 2006; 27: 469-477.
71. Rosen RC, Riley A, Wagner G etal. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
72. Lue TF. Erectile dysfunction. N. Engl. J. Med. 2000; 342: 1802-1813.
73. Kefi A, Demir Ö, Seçil M etal. Doppler ultrasonography in erectile dysfunction patients with risk factors. Turk. J. Urol. 2005; 31: 202-206.
74. Hsieh JT, Lue TF, Muller SC. The influence of blood flow and blood pressure on penile erection. Int. J. Impot. Res. 1989; 1: 35-42.
75. Steers WD, Clemow DB, Persson K etal. The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males. Exp. Physiol. 1999; 84: 137-147.
76. Jin LH, Lee HJ, Shin HY etal. Development and changes with age of detrusor overactivity in spontaneous hypertensive rats as observed by simultaneous registrations of intravesical and intraabdominal pressures. Int. Neurourol. J. 2011; 15: 192-198.
77. Jin LH, Andersson KE, Kwon YH etal. Selection of a control rat for conscious spontaneous hypertensive rats in studies of detrusor overactivity on the basis of measurement of intra-abdominal pressures. Neurourol. Urodyn. 2010; 29: 1338-1343.
78. Ito H, Taga M, Tsuchiyama K etal. IPSS is lower in hypertensive patients treated with angiotensin-II receptor blocker: posthoc analyses of a lower urinary tract symptoms population. Neurourol. Urodyn. 2013; 32: 70-74.
79. Shimizu S, Saito M, Oiwa H etal. Olmesartan ameliorates urinary dysfunction in the spontaneously hypertensive rat via recovering bladder blood flow and decreasing oxidative stress. Neurourol. Urodyn. 2014; 33: 350-357.
80. Lundy A, Lutfi N, Beckey C. Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension. Vasc. Health Risk Manag. 2009; 5: 429-440.
81. Yamashita M, Zhang X, Shiraishi T etal. Determination of percent area density of epithelial and stromal components in development of prostatic hyperplasia in spontaneously hypertensive rats. Urology 2003; 61: 484-489.
82. Nakamura H, Itakura C. Influence of terazosin on the epithelium in the prostate gland of spontaneously hypertensive rats. J. Toxicol. Pathol. 1992; 5: 101-104.
83. Morelli A, Filippi S, Comeglio P etal. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J. Sex. Med. 2010; 7: 107-120.
84. Markham A, Plosker GL, Goa KL. Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60: 955-974.
85. Zhang Q, Radisavljevic ZM, Siroky MB etal. Dietary antioxidants improve arteriogenic erectile dysfunction. Int. J. Androl. 2011; 34: 225-235.
86. Vignozzi L, Morelli A, Filippi S etal. Effect of sildenafil administration on penile hypoxia induced by cavernous neurotomy in the rat. Int. J. Impot. Res. 2008; 20: 60-67.